Joseph Stringer
Stock Analyst at Needham
(2.17)
# 2,760
Out of 4,884 analysts
304
Total ratings
43.75%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $11.48 | +91.64% | 23 | Jul 1, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $320 → $377 | $331.91 | +13.59% | 22 | Jun 26, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $36 → $54 | $48.78 | +10.70% | 13 | Jun 23, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $8.92 | +213.90% | 52 | Jun 6, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $5.41 | +158.78% | 18 | May 22, 2025 | |
| GILD Gilead Sciences | Reiterates: Hold | n/a | $111.75 | - | 6 | May 21, 2025 | |
| ANNX Annexon | Maintains: Buy | $16 → $11 | $2.89 | +280.62% | 19 | May 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $40 → $29 | $18.26 | +58.82% | 20 | May 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $66 → $72 | $65.77 | +9.47% | 24 | May 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | n/a | $459.62 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $55 | $43.00 | +27.91% | 21 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $29.17 | +105.69% | 17 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $33.25 | +170.68% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $0.90 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.26 | +693.65% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $30.49 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $20.95 | +76.61% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $11.15 | +61.43% | 2 | Aug 24, 2021 | |
Stoke Therapeutics
Jul 1, 2025
Reiterates: Buy
Price Target: $22
Current: $11.48
Upside: +91.64%
Alnylam Pharmaceuticals
Jun 26, 2025
Maintains: Buy
Price Target: $320 → $377
Current: $331.91
Upside: +13.59%
Cidara Therapeutics
Jun 23, 2025
Maintains: Buy
Price Target: $36 → $54
Current: $48.78
Upside: +10.70%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $8.92
Upside: +213.90%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $5.41
Upside: +158.78%
Gilead Sciences
May 21, 2025
Reiterates: Hold
Price Target: n/a
Current: $111.75
Upside: -
Annexon
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $2.89
Upside: +280.62%
Apellis Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $18.26
Upside: +58.82%
Rhythm Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $65.77
Upside: +9.47%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $459.62
Upside: -
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $55
Current: $43.00
Upside: +27.91%
Apr 9, 2025
Reiterates: Buy
Price Target: $60
Current: $29.17
Upside: +105.69%
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $33.25
Upside: +170.68%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $0.90
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.26
Upside: +693.65%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $30.49
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $20.95
Upside: +76.61%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $11.15
Upside: +61.43%